A Phase 3 Multicenter Open-label Maintenance Study to Investigate the Long-term Safety of ZS (Sodium Zirconium Cyclosilicate) in Japanese Subjects With Hyperkalemia
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 18 Jul 2019 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned End Date changed from 8 Jul 2019 to 5 Jul 2019.
- 10 Oct 2018 Planned primary completion date changed from 8 Jul 2019 to 5 Jul 2019.